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Smoking related cardiovascular morbidities and cancers are increasing in HIV positive 
individuals due to improved prognosis of HIV infection and high prevalence of smoking. 
More effective smoking cessation programs are therefore needed 1-3. Evidence from 
interventional trials indicates that self-monitoring techniques and motivational support by 
mobile phone-based text messaging may increase quit rates in smokers 4;5. Self-monitoring of 
exhaled carbon monoxide (CO) measurement is a novel approach that may assist motivated 
smokers to quit.  
We investigated whether CO self-monitoring in conjunction with a smoking cessation app 
may improve smoking cessation in HIV positive smokers. We nested a randomized controlled 
into the Swiss HIV Cohort Study 6, and randomly allocated during biannual cohort visits 
patients smoking ≥ 3 cigarettes a day via a trial website to counselling by SHCS centre 
physicians (usual care) or to a combined intervention of CO self-monitoring with mobile 
phone based feedback and app based smoking cessation upport. All participants had to 
provide informed consent to trial participation and fix a quit date within a 2 weeks period 
from the randomisation date. All trial participants irrespective of randomisation received 
standard smoking cessation care consisting of short smoking cessation advices by treating 
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centre physicians, voluntary referral to smoking cessation clinics, and nicotine replacement 
therapy at physician discretion.  
Study nurses assisted patients in the intervention gr up to download the Smokerlzyer® and 
Stop-tabak apps (www.stop-tabak.ch) on their personal mobile phones and assured the 
patient’s registration via a secured channel in the patient communication platform (Jaymob, 
Jackson Mobile Berlin GmbH, Germany) which allowed to activate the iCO Smokerlyzer® 
communication mode. The platform allowed to monitor all CO measurement in a webserver 
that was hosted in a T-system cloud environment and to send reminder messages for CO 
measurements. The IT company provided regular downloads by patient ID with the CO 
measurement, the corresponding dates, and the datesof sent text reminders which were 
transferred to a secured trial data base on the serv r of the University Hospital Basel. 
Patient were instructed how to connect the iCOTM Smokerlyzer® (Bedfont Scientific Ltd, 
England) CO monitoring device with their mobile phone and how to measure the CO content 
in exhaled air. The iCO Smokerlyzer® is a breath test carbon monoxide monitor with a 
replaceable mouth cap intended for single users and serves as a motivational tool to encourage 
smoking cessation. It connects via a USB or headphone plug-in connector to newer generation 
mobile phones and measures the CO content in the exaled air. Instant readings are 
downloaded via app to a personal profile on the phone. Depending on the results of the breath 
test, individualized messages are delivered to enhance maintenance of abstinence or increase 
the motivation to quit. Trial participants received text messages with a request to use the 
personal CO monitor Smokerlyzer® daily for the first 4 weeks, twice weekly for the following 
4 weeks and once weekly from the beginning of the third month to the end of the trial. 
The Stop-tabac.ch app provides advices in all Swiss national languages and English for 
quitting, coping with withdrawal symptoms and relapses and is supported by the Swiss 
Ministry of Health 7 and was used and a supplementary intervention tool in this trial. It offers 
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a coaching function where users receive personalized m ssages that encourage smoking 
cessation and give advice for behavioural change. Th  app offers also options to seek support 
from friends and family and a forum for discussing smoking cessation related issues with 
peers.  
By virtue of the nested trial design all demographic and clinical baseline data and self 
reported smoking data relevant to this trial at baseline and 6 months follow-up were collected 
via routinely biannual cohort visits 6. The primary outcome was the combination of self-
reported continuous abstinence biochemically verified at 6 months by an in-person carbon 
monoxide, with a cut-off of CO in exhaled air of 7 parts per million (ppm) (piCO 
Smokerlyzer CO, Bedfont Scientific Ltd, England) that was done by nursed not blinded for 
treatment status. Self-reported continuous abstinence was defined as no more than five 
cigarettes smoked since the start of the abstinence period at 6 months of follow-up. The 
follow-up examination coincided with the next cohort visit. Self-reported continuous 
abstinence was assessed by physicians during routine 6-month follow-up and directly entered 
into the study’s website. Participants reporting abstinence whose final CO test was positive 
were counted as smokers as were patients with loss of moking status follow-up information. 
Secondary outcomes were differences in the number of daily cigarettes smoked from baseline 
to 6-month follow-up and point prevalence of abstinence (i.e. no smoking in the past 7 days) 
at 6-month follow-up.  
Based on self reported quit rates from users of the s opp tabab.ch app (8%) we assumed that 
our combined intervention with additional CO self monitoring would lead to a sic months quit 
rate of 12 % and 5% in the control group, respectivly. With a significance level of α = 0.05 
(two-sided) and a power of 0.8 a total of 496 patients were needed.   
The primary intention to treat analysis was performed on the basis of a self-reported 
continuous abstinence (defined as no more than five cigarettes since the start of the abstinence 
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period) biochemically verified by a CO breath test at 6 months of follow-up. Patients with 
missing data or a positive CO breath test at 6 months follow-up were counted as smokers. 
Analysis was by logistic and linear regression for smoking cessation rates and difference in 
daily cigarette consumption at 6 months follow-up, respectively with adjustment for past self-
reported history of smoking cessation, numbers of cigarettes smoked at trial start, and 
prescribed nicotine replacement or drugs against withdrawal symptoms. All analyses were 
done in R version 3.5.2. The trial protocol was approved by Swiss Ethcs and registered at 
ClinicalTrials.gov, ID NCT02840513. 
At the start of the trial on June 1st 2017 3293 of 10,493 (34%) patients in the SHCS smoked 
≥3 cigarettes and these 2444 (74%) indicated at any cohort visit in the previous 48 months to 
have quit once and then resumed smoking. During a recruitment period of 1.5 years, 1807 
patients were screened for inclusion and a total of 81 patients were enrolled (Figure 1). Trial 
participants compared to the remaining smoking population in the SHCS were better educated, 
had more previous quit attempts, smoked more cigarettes and were more frequently men 
having sex with men (MSM), but less frequently IV drug users (Table 1). Six of 42 (14%) 
participants in the intervention group and five of 39 (13%) in the standard of care group quit 
smoking at 6 months follow-up (adjusted OR 1.06, 95% CI 0.29; - 3.86) and three participant 
were lost to follow-up. Based on 12 months cohort data one individual had resumed smoking 
and five trial participants reported to have quit smoking. The adjusted mean difference in 
smoked cigarettes between the intervention and control groups at 6 months was -1.38 (95% CI 
-4.45; 1.69). 
In total 24 (57%) and 18 (46%) patients in the intervention and control groups received 
nicotine replacement therapy. Eleven (26%) of the participants in the intervention group sent 
at least one result of a CO measurement with the Smokerlyzer App (median 22.5 (IQR 6- 63)). 
Twelve (28.5%) participants in the intervention group reported using the Stop-tabac.ch app 
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multiple times a week during the first month of theintervention. Of all the remaining smokers 
in the cohort who did not participate in the trial, 53 (1.6%) had reported during the trial 
recruitment period not to be smoking at the next 6 months cohort visit and 78 (2.4%) at the 12 
months visit. The trial was terminated prematurely due to insufficient patient recruitment and 
lack of funding. 
Results from this pragmatic trial remained inconclusive and underpowered due to recruitment 
difficulties although the nested trial design allowed for the potential to recruit from a large 
group of smokers with a self reported history for quitting. Patients included in the trial 
reported more cessation attempts than non-participants which was identified as the best 
predictor for successful quitting from observational d ta analysis of the SHCS 8. This 
information, however, did not translate into a high recruitment rate. Forcing patients to fix a 
quit date in a time window of two weeks following the cohort visit may have distracted not 
optimally motivated patients ready to immediately tr o quit. Installation of smoking 
cessation and CO monitoring apps was time consuming a d many patients indicated 
difficulties in using the CO monitoring device. The igh variety of mobile phone models and 
operating systems created compatibility problems with the CO device, some of which were 
hard to identify during the initial setup and installation. Integrating this intervention into the 
routine of busy infectious disease clinics turned out t  be very demanding for clinicians and 
staff. Nevertheless, 11% of the trial population – irrespective of the intervention – quit which 
is considerable higher than the 1.6% smokers in the remaining cohort who had indicated to 
have quit. 
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Table 1 Baseline characteristics of trial participants and of the entire smoking population in the Swiss HIV Cohort Study  
  Trial 
participants 
Intervention Control Smokers in cohort 
Randomized to trial/ entire cohort (n) 81 42 39 3293 
Males (n, %) 68 (84%) 36 (86%) 32 (82%) 2489 (76%) 
Age (median (IQR)) 47 (40-52) 47.5 (41-52) 47 (40-52) 50 (42- 550) 
Education ≥ 9 years (n, %) 62 (77%) 31 (74%) 31 (80%) 2338 (74%) + 
Pack years (median (IQR)) 15 (9-25) 15 (9-26) 16 (7.5-24) 18 (10- 25) § 
Cigarettes smoked (median (IQR)) 17 (10-20) 15.5 (10-20) 20 (10-20) 15 (10-20) 
Previous attempt to quit smoking 
(n, %) 
23 (28%) 12 (29%) 11 (28%) 695 (21%) 
Framingham risk score      
<10% 48 (59%) 25 (59.5%) 23 (59%) 1855 (56.3%) 
10-19% 25 (31%) 14 (33.3%) 11 (28%) 985 (30%) 
>20% 6 (7.5%) 2 (4.8%) 4 (10%) 449 (13.6%) 
missing 2 (2.5%) 1 (2.4%) 1 (3%) 4 (0.1%) 
Previous CV event (n, %) 10 (12%) 7 (17%) 3 (7.7%) 301 (9.1%) 
On ART (n, %) 81 (100%) 402 (100%) 39 (100%) 3169 (96%) ǂ 
Previous AIDS event (n, %) 14 (17%) 6 (14%) 8 (21%) 721 (22%) 
CD4 start cells/µl (median (IQR)) 732 (540-960) 754 (537-975) 696 (556-936) 704 (507-926) ¥ 
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RNA viral load >20 copies/ml (n, %) 8 (10%) 3 (7%) 5 (13%) 321 (10%)5 
RNA viral load >400 copies/ml 
(n, %) 
2 (2.5%) 1 (2.6%) 1 (2.4%) 98 (3%) ¢ 
Current IV drug use (n, %) 7 (9%) 3 (7%) 4 (10%) 359 (10.9%) 
Source of infection (n, %)     
Men having sex with men 41 (51%) 22 (52%) 19 (49%) 1433 (44%) 
Heterosexual 27 (33%) 16 (38%) 11 (28%) 983 (30%) 
Intravenous drug use 9 (11%) 2 (5%) 7 (18%) 732 (22%) 
Other source 4 (5%) 2 (5%) 2 (5%) 145 (4%) 
+ Missing 122 values; § Missing 249 values; ǂ Missing 36 values;¥ Missing 17 values;¢ Missing 31 values 
Baseline for trial participants refers to the date of randomisation and for the cohort population to the date of trial start  
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